Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Hinchey Calls On FDA To Investigate Agency Knowledge Of Prozac Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. Maurice Hinchey (D-N.Y.) requests that FDA conduct an investigation into what the agency did or did not know about Lilly documents regarding a possible link between Prozac (fluoxetine) and increased suicidality and violence
Advertisement

Related Content

British Medical Journal Apologizes To Lilly For Prozac Article
British Medical Journal Apologizes To Lilly For Prozac Article
Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims
Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims
Prozac Documents Deemed "Missing" Were Already Available, Lilly Says
Prozac Documents Deemed "Missing" Were Already Available, Lilly Says
“Missing” Lilly Documents Under Review By Rep. Hinchey
“Missing” Lilly Documents Under Review By Rep. Hinchey
FDA Antidepressant Safety Plan Includes "Black Box," Unit-Of-Use Packaging
FDA Approps Amendment Targets Chief Counsel Troy; Pfizer Ties Challenged

Topics

Advertisement
UsernamePublicRestriction

Register

PS061036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel